8-K
filed November 12, 2024, 6:59 PM ET
ticker ASRT
CIK 0001808665
earnings
confidence high
sentiment neutral
materiality 0.60
Assertio Q3 net sales $28.7M, adj EBITDA $5.3M; board adds Stark, loses Staple/Vacirca
Assertio Holdings, Inc.
2024-Q3 EPS reported
-$0.12
revenue$92,778,000
- Q3 net product sales $28.7M vs $35.1M YoY; net loss $2.9M vs $279.5M loss (prior year impairment).
- Rolvedon net sales $15.0M (stable vs $15.1M Q2); Indocin $5.7M (down from $6.9M Q2) on generic competition.
- Adjusted EBITDA $5.3M (down from $12.9M YoY); adjusted EPS $0.03 vs $0.01 YoY.
- Cash and short-term investments $88.6M; debt $40M (6.5% convertible notes, maturity 2027).
- Board changes: Staple/Vacirca departed Nov 7; Mason appointed Chair; Stark (ex-Teva CLO) named independent director.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter Staple retired as Director at Assertio Holdings, Inc..
- Action
- retired
- Role
- Director
Exact text from the filing
On November 7, 2024, Peter Staple notified the Board of Directors (the “Board”) of the Company of his intent to retire as a member of the Board, effective November 7, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey Vacirca retired as Director at Assertio Holdings, Inc..
- Action
- retired
- Role
- Director
Exact text from the filing
On November 7, 2024, Jeffrey Vacirca also notified the Board of the Company of his intent to retire as a member of the Board and its committees, effective as of the Effective Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Stark was appointed as Director at Assertio Holdings, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On November 7, 2024, the Board appointed David Stark to the Board, effective as of the Effective Date.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.